Oculis Holding AG (ICE: OCS)

Iceland flag Iceland · Delayed Price · Currency is ISK
3,140.00
0.00 (0.00%)
At close: Jan 17, 2025
82.56%
Market Cap 134.39B
Revenue (ttm) 138.64M
Net Income (ttm) -11.12B
Shares Out n/a
EPS (ttm) -285.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 552,798
Average Volume 220,201
Open 3,140.00
Previous Close 3,140.00
Day's Range 3,040.00 - 3,180.00
52-Week Range 1,500.00 - 1,850.00
Beta n/a
RSI 76.37
Earnings Date Mar 10, 2025

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneratio... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Riad Sherif
Employees 36
Stock Exchange Nasdaq Iceland
Ticker Symbol OCS
Full Company Profile

Financial Performance

In 2023, Oculis Holding AG's revenue was 883,000, a decrease of -3.18% compared to the previous year's 912,000. Losses were -88.80 million, 129.5% more than in 2022.

Financial numbers in CHF Financial Statements

News

There is no news available yet.